FFC#6/2020

Validation of the distribution and activity of new optimized leads in mouse model and other CF model systems

AREA 1 Therapies to correct the underlying defect

FFC#6/2020

Validation of the distribution and activity of new optimized leads in mouse model and other CF model systems
€ 0 still needed
0%
€ 90.000 goal

pRINCIPAL INVESTIGATOR

Laura Lentini (Università degli Studi di Palermo, STEBICEF – Sez. di Biologia)

Partner

Ivana Pibiri (Università degli Studi di Palermo, STEBICEF – Sez. di Chimica)

Researchers

11

Category

AREA 1 Therapies to correct the underlying defect

Duration

2 years

Goal

€ 90.000

Funds raised

€ 90.000

Objectives

The CFTR stop mutations imply a “stop” signal in the CFTR protein synthesis, that turns out to be incomplete and it is eliminated by the cell’s quality control system. This research group, thanks a previous project (FFC#3/2017), has developed three molecules which are capable of effectively overcoming the DNA’s stop signal (due to several mutations) in vitro, thus allowing the complete protein’s synthesis. The new project intends to launch a preclinical study in transgenic mouse model containing the UGA-stop signal in the DNA, in order to evaluate the molecules’ efficacy in vivo. Furthermore, it is within the goals of the present project to evaluate the distribution of those substances in vivo, in the animal model organism, so to study also the molecules’ mechanism of action.

who adopted the project

Delegazione FFC di Palermo e Trapani

€ 90.000

Delegazione FFC di Catania Mascalucia

€ 21.500

Delegazione FFC di Vigevano

€ 47.000

OTHER PROJECTS

Discover the other projects

GMRF#1/2026

Exploring the role of PKD1 in promoting CFTR stability and function at the cell surface

FFC#1/2026

Mapping proteins regulating CFTR mRNA stability to identify new therapeutic targets for nonsense mutations

FFC#2/2026

Evaluating the potential of phosphodiesterase inhibitors to enhance the efficacy of CFTR modulators and support personalized therapeutic approaches